India covid-19 2020 patient travelers India

Glenmark, Cipla gain from covid drugs though slowing pharma sales a concern

Reading now: 299
www.livemint.com

pharma market once again showing signs of slowing sales, drugs such as Favipiravir, Remdesivir and Toclizumab contributed to the growth of sales for Glenmark Pharmaceutical Ltd, Cipla Ltd and Cadila Healthcare Ltd.

These companies clocked sales growth between 7% and 15% in November.In contrastingl, the broader Indian pharma market sales growth decelerated considerably in November, which is a surprise given that last month growth had bounced back.

Sales growth slipped to about 1.3% in November as against 9.8% in October. Note that growth in September stood at 4.7% starting to show a rebound.Volumes have started to taper off post the monsoon season.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA